Show simple item record

dc.contributor.authorPetkovic, Vibor
dc.contributor.authorLochmatter, Didier
dc.contributor.authorTurton, James P
dc.contributor.authorClayton, Peter E
dc.contributor.authorTrainer, Peter J
dc.contributor.authorDattani, Mehul T
dc.contributor.authorEblé, Andrée
dc.contributor.authorRobinson, Iain C
dc.contributor.authorFlück, Christa E
dc.contributor.authorMullis, Primus E
dc.date.accessioned2009-06-09T16:44:02Z
dc.date.available2009-06-09T16:44:02Z
dc.date.issued2007-11
dc.identifier.citationExon splice enhancer mutation (GH-E32A) causes autosomal dominant growth hormone deficiency. 2007, 92 (11):4427-35 J. Clin. Endocrinol. Metab.en
dc.identifier.issn0021-972X
dc.identifier.pmid17726075
dc.identifier.doi10.1210/jc.2007-0857
dc.identifier.urihttp://hdl.handle.net/10541/70041
dc.description.abstractCONTEXT AND OBJECTIVE: Alteration of exon splice enhancers (ESE) may cause autosomal dominant GH deficiency (IGHD II). Disruption analysis of a (GAA) (n) ESE motif within exon 3 by introducing single-base mutations has shown that single nucleotide mutations within ESE1 affect pre-mRNA splicing. DESIGN, SETTING, AND PATIENTS: Confirming the laboratory-derived data, a heterozygous splice enhancer mutation in exon 3 (exon 3 + 2 A-->C) coding for GH-E32A mutation of the GH-1 gene was found in two independent pedigrees, causing familial IGHD II. Because different ESE mutations have a variable impact on splicing of exon 3 of GH and therefore on the expression of the 17.5-kDa GH mutant form, the GH-E32A was studied at the cellular level. INTERVENTIONS AND RESULTS: The splicing of GH-E32A, assessed at the protein level, produced significantly increased amounts of 17.5-kDa GH isoform (55% of total GH protein) when compared with the wt-GH. AtT-20 cells coexpressing both wt-GH and GH-E32A presented a significant reduction in cell proliferation as well as GH production after forskolin stimulation when compared with the cells expressing wt-GH. These results were complemented with confocal microscopy analysis, which revealed a significant reduction of the GH-E32A-derived isoform colocalized with secretory granules, compared with wt-GH. CONCLUSION: GH-E32A mutation found within ESE1 weakens recognition of exon 3 directly, and therefore, an increased production of the exon 3-skipped 17.5-kDa GH isoform in relation to the 22-kDa, wt-GH isoform was found. The GH-E32A mutant altered stimulated GH production as well as cell proliferation, causing IGHD II.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBlotting, Western
dc.subject.meshBody Height
dc.subject.meshCell Proliferation
dc.subject.meshCell Survival
dc.subject.meshCells, Cultured
dc.subject.meshChromosome Disorders
dc.subject.meshEndoplasmic Reticulum
dc.subject.meshExons
dc.subject.meshFemale
dc.subject.meshForskolin
dc.subject.meshGenes, Dominant
dc.subject.meshGenetic Vectors
dc.subject.meshGolgi Apparatus
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMicroscopy, Confocal
dc.subject.meshMutation
dc.subject.meshPedigree
dc.subject.meshProtein Isoforms
dc.subject.meshRNA, Messenger
dc.subject.meshSecretory Vesicles
dc.titleExon splice enhancer mutation (GH-E32A) causes autosomal dominant growth hormone deficiency.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pediatric Endocrinology, Diabetology, and Metabolism, Inselspital, University Children's Hospital, CH-3010 Bern, Switzerland.en
dc.identifier.journalThe Journal of Clinical Endocrinology and Metabolismen
html.description.abstractCONTEXT AND OBJECTIVE: Alteration of exon splice enhancers (ESE) may cause autosomal dominant GH deficiency (IGHD II). Disruption analysis of a (GAA) (n) ESE motif within exon 3 by introducing single-base mutations has shown that single nucleotide mutations within ESE1 affect pre-mRNA splicing. DESIGN, SETTING, AND PATIENTS: Confirming the laboratory-derived data, a heterozygous splice enhancer mutation in exon 3 (exon 3 + 2 A-->C) coding for GH-E32A mutation of the GH-1 gene was found in two independent pedigrees, causing familial IGHD II. Because different ESE mutations have a variable impact on splicing of exon 3 of GH and therefore on the expression of the 17.5-kDa GH mutant form, the GH-E32A was studied at the cellular level. INTERVENTIONS AND RESULTS: The splicing of GH-E32A, assessed at the protein level, produced significantly increased amounts of 17.5-kDa GH isoform (55% of total GH protein) when compared with the wt-GH. AtT-20 cells coexpressing both wt-GH and GH-E32A presented a significant reduction in cell proliferation as well as GH production after forskolin stimulation when compared with the cells expressing wt-GH. These results were complemented with confocal microscopy analysis, which revealed a significant reduction of the GH-E32A-derived isoform colocalized with secretory granules, compared with wt-GH. CONCLUSION: GH-E32A mutation found within ESE1 weakens recognition of exon 3 directly, and therefore, an increased production of the exon 3-skipped 17.5-kDa GH isoform in relation to the 22-kDa, wt-GH isoform was found. The GH-E32A mutant altered stimulated GH production as well as cell proliferation, causing IGHD II.


This item appears in the following Collection(s)

Show simple item record